solute carrier family 17 member 9Genealiases: C20orf59 · POROK8 · VNUT
Q-omics provides the consensus-scored SLC17A9 profile across patient tissues and cancer cell-line models. SLC17A9 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC17A9 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SLC17A9 RNA expression shows 20,029 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where SLC17A9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC17A9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC17A9 survival associations across molecular data types. SLC17A9 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC17A9 RNA expression–survival associations across cancer types. High SLC17A9 expression shows unfavorable associations in KIRC, UVM, ACC and LGG, but favorable associations in HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC17A9 RNA expression.
This table summarizes SLC17A9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC17A9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC17A9 shows higher tumor expression in KIRC, HNSC, COAD, THCA, STAD and LUAD. The KIRC box plot shows higher SLC17A9 RNA expression in tumor versus normal tissue (log2 FC = +1.707, t-test p < 0.001).
This table shows molecular features associated with SLC17A9 in patient tissues and cancer cell lines. In patient samples, SLC17A9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC17A9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
